Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have received an average recommendation of “Moderate Buy” from the five analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $7.38.

MRVI has been the subject of several research analyst reports. TD Cowen started coverage on shares of Maravai LifeSciences in a research report on Monday, October 5th. They issued a “buy” rating and a $9.00 price objective for the company. UBS Group increased their price objective on Maravai LifeSciences from $2.50 to $8.00 and gave the company a “neutral” rating in a research report on Wednesday, September 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a research note on Wednesday, August 26th. Wall Street Zen downgraded Maravai LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, August 29th. Finally, Wells Fargo & Company upped their price target on Maravai LifeSciences from $5.50 to $6.50 and gave the company an “overweight” rating in a research note on Friday, August 7th.

Key Headlines Impacting Maravai LifeSciences

Here are the key news stories impacting Maravai LifeSciences this week:

• Positive Sentiment: Maravai reported a third-quarter loss of $0.03 per share, narrower than analyst estimates of a $0.05–$0.06 loss and the $0.08 loss a year earlier. Revenue of $45.85 million also exceeded the $43.56 million consensus estimate. Article: Maravai LifeSciences Reports Q3 Loss, Beats Revenue Estimates
• Positive Sentiment: The company raised its earnings guidance for 2026, signaling improved expectations for the full year and providing a positive forward-looking catalyst. Article: Maravai Raises 2026 Earnings Guidance
• Neutral Sentiment: The earnings call transcript and presentation provide further management commentary on the quarter and outlook, but the available article details do not specify additional guidance figures or explanations. Article: Q3 2026 Earnings Call Transcript
• Negative Sentiment: Despite the quarterly improvement, Maravai still posted a loss; its reported net margin was negative 37.07% and return on equity was negative 15.70%. Ongoing unprofitability remains a risk for investors. Article: Maravai Reports Third Quarter 2026 Financial Results

Institutional Investors Weigh In On Maravai LifeSciences

Several institutional investors have recently modified their holdings of the business. Royal Bank of Canada grew its holdings in Maravai LifeSciences by 49.0% during the 1st quarter. Royal Bank of Canada now owns 9,761 shares of the company’s stock worth $27,000 after acquiring an additional 3,209 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Maravai LifeSciences by 15.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 27,185 shares of the company’s stock valued at $208,000 after acquiring an additional 3,709 shares during the last quarter. Ethic Inc. lifted its stake in shares of Maravai LifeSciences by 57.1% in the 3rd quarter. Ethic Inc. now owns 16,654 shares of the company’s stock valued at $128,000 after purchasing an additional 6,050 shares during the period. State of Alaska Department of Revenue acquired a new position in shares of Maravai LifeSciences in the 3rd quarter valued at $47,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Maravai LifeSciences in the 3rd quarter worth $58,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

Maravai LifeSciences Stock Down 9.6%

Shares of MRVI opened at $6.98 on Friday. The company has a market capitalization of $1.81 billion, a P/E ratio of -16.23 and a beta of 0.61. Maravai LifeSciences has a one year low of $2.55 and a one year high of $9.42. The business’s 50 day simple moving average is $7.38 and its 200-day simple moving average is $5.31. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.05 and a quick ratio of 2.98.

Maravai LifeSciences (NASDAQ:MRVI) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03. Maravai LifeSciences had a negative return on equity of 12.23% and a negative net margin of 30.83%. The firm had revenue of $45.85 million during the quarter, compared to analysts’ expectations of $43.56 million. As a group, sell-side analysts predict that Maravai LifeSciences will post -0.18 EPS for the current fiscal year.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc is a life sciences company that provides products and services used in the development, manufacture and quality testing of biopharmaceuticals, vaccines and diagnostic products. The company serves pharmaceutical, biotechnology, academic and other research organizations involved in nucleic acid and biologics development.

Through its TriLink BioTechnologies business, Maravai supplies specialized nucleic acid products and services, including modified nucleotides, messenger RNA-related materials, enzymes and other components used in research and biomanufacturing.